Adiponectin as a potential therapeutic agent for nonalcoholic steatohepatitis

Hepatology Research

Volumn 40, Issue 4, 2010, Pages 446-447

  Polyzos, Stergios A ^a   Kountouras, Jannis ^a   Zavos, Christos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; RECOMBINANT ADIPONECTIN; UNCLASSIFIED DRUG;

HEPATOMEGALY; LETTER; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER PROTECTION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; STEATOSIS;

EID: 77954351876     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00632.x     Document Type: Letter

References (13)

1. Fukushima J, Kamada Y, Matsumoto H. Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization. Hepatol Res 2009, 39:724-38.
2. Shiota G. Adiponectin as a therapeutic target of non-alcoholic steatohepatitis. Hepatol Res 2009, 39:951-3.
3. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001, 7:947-53.
4. Yamauchi T, Kamon J, Waki H. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-6.
5. Wang Y, Xu A, Knight C, Xu LY, Cooper GJ. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J Biol Chem 2002, 277:19521-9.
6. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003, 112:91-100.
7. Sennello JA, Fayad R, Morris AM. Regulation of T cell-mediated hepatic inflammation by adiponectin and leptin. Endocrinology 2005, 146:2157-64.
8. Massip-Salcedo M, Zaouali MA, Padrissa-Altes S. Activation of peroxisome proliferator-activated receptor-alpha inhibits the injurious effects of adiponectin in rat steatotic liver undergoing ischemia-reperfusion. Hepatology 2008, 47:461-72.
9. Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of nonalcoholic fatty liver disease. Diabetes Obes Metab 2009
10. Sohara N, Takagi H, Kakizaki S, Sato K, Mori M. Elevated plasma adiponectin concentrations in patients with liver cirrhosis correlate with plasma insulin levels. Liver Int 2005, 25:28-32.
11. Asada K, Yoshiji H, Noguchi R. Crosstalk between high-molecular-weight adiponectin and T-cadherin during liver fibrosis development in rats. Int J Mol Med 2007, 20:725-9.
12. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009, 72:299-314.
13. Narasimhan ML, Coca MA, Jin J. Osmotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor. Mol Cell 2005, 17:171-80.